Skip to main content
Top
Published in: Diabetologia 4/2021

Open Access 01-04-2021 | Disorders of Intellectual Development | Article

Poor glycaemic control is associated with increased risk of neurodevelopmental disorders in childhood-onset type 1 diabetes: a population-based cohort study

Authors: Shengxin Liu, Ralf Kuja-Halkola, Henrik Larsson, Paul Lichtenstein, Jonas F. Ludvigsson, Ann-Marie Svensson, Soffia Gudbjörnsdottir, Magnus Tideman, Eva Serlachius, Agnieszka Butwicka

Published in: Diabetologia | Issue 4/2021

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to investigate the effect of childhood-onset type 1 diabetes on the risk of subsequent neurodevelopmental disorders, and the role of glycaemic control in this association. We hypothesised that individuals with poor glycaemic control may be at a higher risk of neurodevelopmental disorders compared with the general population, as well as compared with individuals with type 1 diabetes with adequate glycaemic control.

Methods

This Swedish population-based cohort study was conducted using data from health registers from 1973 to 2013. We identified 8430 patients with childhood-onset type 1 diabetes (diagnosed before age 18 years) with a median age of diabetes onset of 9.6 (IQR 5.9–12.9) and 84,300 reference individuals from the general population, matched for sex, birth year and birth county. Cox models were used to estimate the effect of HbA1c on the risk of subsequent neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorders (ASD) and intellectual disability.

Results

During a median follow-up period of 5.6 years, 398 (4.7%) individuals with type 1 diabetes received a diagnosis of any neurodevelopmental disorder compared with 3066 (3.6%) in the general population, corresponding to an adjusted HR (HRadjusted) of 1.31 (95% CI 1.18, 1.46) after additionally adjusting for other psychiatric morbidity prior to inclusion, parental psychiatric morbidity and parental highest education level. The risk of any neurodevelopmental disorder increased with HbA1c levels and the highest risk was observed in patients with mean HbA1c >8.6% (>70 mmol/mol) (HRadjusted 1.90 [95% CI 1.51, 2.37]) compared with reference individuals without type 1 diabetes. In addition, when compared with patients with diabetes with HbA1c <7.5% (<58 mmol/mol), patients with HbA1c >8.6% (>70 mmol/mol) had the highest risk of any neurodevelopmental disorder (HRadjusted 3.71 [95% CI 2.75, 5.02]) and of specific neurodevelopmental disorders including ADHD (HRadjusted 4.16 [95% CI 2.92, 5.94]), ASD (HRadjusted 2.84 [95% CI 1.52, 5.28]) and intellectual disability (HRadjusted 3.93 [95% CI 1.38, 11.22]).

Conclusions/interpretation

Childhood-onset type 1 diabetes is associated with an increased risk of neurodevelopmental disorders, with the highest risk seen in individuals with poor glycaemic control. Routine neurodevelopmental follow-up visits should be considered in type 1 diabetes, especially in patients with poor glycaemic control.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference International Diabetes Federation (2019) IDF Diabetes Atlas, 9th edn. International Diabetes Federation, Brussels International Diabetes Federation (2019) IDF Diabetes Atlas, 9th edn. International Diabetes Federation, Brussels
5.
go back to reference American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Association, Washington, D.C.CrossRef American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5, 5th edn. American Psychiatric Association, Washington, D.C.CrossRef
32.
go back to reference Dennis EL, Thompson PM (2013) Typical and atypical brain development: a review of neuroimaging studies. Dialogues Clin Neurosci 15(3):359–384CrossRef Dennis EL, Thompson PM (2013) Typical and atypical brain development: a review of neuroimaging studies. Dialogues Clin Neurosci 15(3):359–384CrossRef
36.
38.
go back to reference World Health Organization (2011) Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. World Health Organization, Geneva World Health Organization (2011) Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. World Health Organization, Geneva
Metadata
Title
Poor glycaemic control is associated with increased risk of neurodevelopmental disorders in childhood-onset type 1 diabetes: a population-based cohort study
Authors
Shengxin Liu
Ralf Kuja-Halkola
Henrik Larsson
Paul Lichtenstein
Jonas F. Ludvigsson
Ann-Marie Svensson
Soffia Gudbjörnsdottir
Magnus Tideman
Eva Serlachius
Agnieszka Butwicka
Publication date
01-04-2021
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 4/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-020-05372-5

Other articles of this Issue 4/2021

Diabetologia 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine